This finding suggests that NK cells and Sorafenib may hinder each other's ability against HCC tumor growth by modulating JAK/STAT, PI3K/AKT/mTOR, Ras/Raf/ERK/MEK or Wnt/β-catenin pathways, thereby affecting the expression of Bcl-2, Mcl-1, cyclin D1, and survivin levels. Here, BCL2 is linked to neoplasm.